J. Pinkert

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors

Anna Rachel Minchom, Olof Lindén, Daan G. Knapen, Raffit Hassan et autres

INTRODUCTION: Th-anetumab corixetan; mesothelin-targeting antibody-chelator conjugate (MSLN-TTC)] is a targeted alpha therapy consisting of a fully human mesothelin-targeting monoclonal antibody conjugated with a 3,2-hydroxypyridinone (3,2-HOPO) chelator radiolabeled with the alpha particle-emitting radionuclide thorium-227. This phase I study determined the safety, pharmacokinetics, and …

gb, se, nl, us, fi, de (code pays fourni par la source)

Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): Final results from a prospective, noninterventional study (PARABO)

HOLGER PALMEDO, Susanne Martina Eschmann, Andreas Niesen, Julia Schönberger et autres

Ziel/Aim PARABO (NCT02398526), a prospective, single-arm, observational study, assessed pain outcomes in German patients with mCRPC who received Ra-223 in real-life clinical practice setting. Methodik/Methods Outcomes include clinically meaningful pain response, ie, a≥2-point improvement in Brief Pain Inventory short form (BPI-SF) worst …

de, us (code pays fourni par la source)

Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study

HOLGER PALMEDO, Susanne Martina Eschmann, F. Straube, Andreas Niesen et autres

Ziel/Aim Ra-223 is a bone targeted alpha emitter which showed a significant survival advantage and favorable safety profile in a phase 3 trial. Ra-223 also delayed opioid use and external beam radiotherapy in post hoc analyses of that trial. PARABO (NCT02398526) is …

de, us (code pays fourni par la source)

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

J. Pinkert, Hans-Henning Boehm, Mark Trautwein, Wolf‐Dietrich Doecke et autres

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a cell surface receptor, is expressed on normal epithelial tissue and highly expressed in cancers of high unmet medical need, such as non-small cell lung, pancreatic, and colorectal cancer. CEACAM receptors undergo homo- and heterophilic …

de (code pays fourni par la source)

594P Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study

HOLGER PALMEDO, Hojjat Ahmadzadehfar, Susanne Martina Eschmann, Ivan Selkinski et autres

de, us (code pays fourni par la source)

Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Joerg Willuda, Hans-Henning Boehm, J. Pinkert, Mark Trautwein et autres

CEACAM6 (CD66c) is a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors. CEACAM6 is expressed on tumor cells of multiple malignancies e.g.adenocarcinomas of the lung, colon, pancreas and stomach. In these tumor types higher CEACAM6 expression is …

de (code pays fourni par la source)

Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

Joerg Willuda, Hans-Henning Boehm, J. Pinkert, Mark Trautwein et autres

Abstract CEACAM6 (CD66c) is a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors. CEACAM6 is expressed on tumor cells of multiple malignancies e.g.adenocarcinomas of the lung, colon, pancreas and stomach. In these tumor types higher CEACAM6 expression …

de (code pays fourni par la source)

Abstract 1771: BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c)

Joerg Willuda, Mark Trautwein, J. Pinkert, Wolf‐Dietrich Doecke et autres

Abstract CEACAM6 (CD66c) was previously shown to act as a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors (Witzens-Harig et al., Blood 2013). CEACAM6 is a GPI-linked protein that is strongly expressed at the tumor cell surface …

de (code pays fourni par la source)

First interim results of PARABO: A non-interventional study evaluating patients with mCRPC with bone metastases treated with Radium-223 (Xofigo®) in a real life German practice setting

HOLGER PALMEDO, Susanne Martina Eschmann, Anke Werner, I. Selinski et autres

Pre- and intratherapeutical ibritumomab tiuxetan Zevalin® dosimetry in childhood.

Christian Happel, Justin M. Diener, W. Tilman Kranert, Benjamin Bockisch et autres

Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors

Ursula Nestle, Klemens Scheidhauer, C. Puskás, Elena Ballek et autres

AIM: Although predictive factors (PF) for conventional lymphoma therapy are established and frequently used in clinical practice and medical research, the PF for radioimmunotherapy (RIT) have not been fully defined until now. The aim of this multicenter evaluation is to prove the …

de (code pays fourni par la source)

Physical aspects of scintigraphybased dosimetry for nuclear medicine therapy

Andrea Schaefer, B. O. Knoop, J. Pinkert, Michail Plotkin et autres

In nuclear medicine therapy the treatment of tumours by radiation exposure from internally deposited labelled antibodies or labelled peptides is currently an active field of investigation. To permit the efficient delivery of high amounts of radiation dose to tumours while limiting the …

us, de (code pays fourni par la source)